Skip to main content
. 2020 Mar 11;80(6):587–600. doi: 10.1007/s40265-020-01285-0

Fig. 6.

Fig. 6

Mean change in bodyweight from baseline at week 12 and 24 across the treatment groups. Mean change in bodyweight from baseline to week 12 and 24 of modified intent-to-treat population. Data shown as least-squares mean (95% confidence interval); intergroup comparison p value; group 1, remogliflozin etabonate 100 mg; group 2, remogliflozin etabonate 250 mg; group 3, dapagliflozin 10 mg